Patents by Inventor Knud Erik Andersen

Knud Erik Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8846677
    Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: September 30, 2014
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
  • Patent number: 8501739
    Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: August 6, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
  • Publication number: 20130079340
    Abstract: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions.
    Type: Application
    Filed: October 25, 2012
    Publication date: March 28, 2013
    Inventors: Florencio Zaragoza Dorwald, Rolf Hohlweg, Inge Thoger Christensen, Jane Marie Lundbeck, Knud Erik Andersen
  • Patent number: 8394842
    Abstract: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings,! of the general formula (1): having histamine H3 antagonistic activity can be used in pharmaceutical compositions.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: March 12, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Florencio Zaragoza Dorwald, Rolf Hohlweg, Inge Thoger Christensen, Jane Marie Lundbeck, Knud Erik Andersen
  • Publication number: 20120232078
    Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
    Type: Application
    Filed: May 15, 2012
    Publication date: September 13, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
  • Publication number: 20110009420
    Abstract: The present invention provides compounds of the formula wherein R1, R2 and B are as herein described, pharmaceutical compositions comprising these compounds, use of these compounds for the preparation of pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of disorders and diseases wherein modulation of the H3 receptor is beneficial.
    Type: Application
    Filed: September 16, 2010
    Publication date: January 13, 2011
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventor: Knud Erik Andersen
  • Patent number: 7799924
    Abstract: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of disorders in which a histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 21, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Jan Lindy Sorensen, Knud Erik Andersen, Ingrid Pettersson
  • Publication number: 20090312309
    Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
    Type: Application
    Filed: June 30, 2006
    Publication date: December 17, 2009
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
  • Publication number: 20080113968
    Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Application
    Filed: April 10, 2007
    Publication date: May 15, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sorensen
  • Patent number: 7332508
    Abstract: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of disorders in which a histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: February 19, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Jan Lindy Sorensen, Knud Erik Andersen, Ingrid Pettersson
  • Patent number: 7208497
    Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: April 24, 2007
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sørensen
  • Patent number: 6908926
    Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: June 21, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist
  • Patent number: 6756384
    Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: June 29, 2004
    Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbH
    Inventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
  • Publication number: 20040019039
    Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Application
    Filed: June 27, 2002
    Publication date: January 29, 2004
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sorensen
  • Patent number: 6610721
    Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 26, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Florencio Zaragoza Dorwald
  • Publication number: 20030135056
    Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Application
    Filed: July 23, 2002
    Publication date: July 17, 2003
    Inventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
  • Patent number: 6569849
    Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula wherein X, Y, Z, A, R1, R2, r and s are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to secretion and circulation of insulin antagonising peptides.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: May 27, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Tine Krogh Jorgensen, Rolf Hohlweg, Peter Madsen, Knud Erik Andersen, Svend Treppendahl, Uffe Bang Olsen, Zdenek Polivka, Alexandra Silhankova, Karel Sindelar, Vladimir Valenta, Tomas Kalisz
  • Publication number: 20020151539
    Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula 1
    Type: Application
    Filed: March 14, 2002
    Publication date: October 17, 2002
    Inventors: Tine Krogh Jorgensen, Knud Erik Andersen, Rolf Hohlweg, Uffe Bang Olsen, Erik Fischer, Zdenek Polivka, Kaler Sindelar
  • Patent number: 6437147
    Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 20, 2002
    Assignees: Novo Nordisk, Boehringer Ingelheim International GmbH
    Inventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
  • Patent number: 6417218
    Abstract: A class of substituted imidazole compounds of formula I methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor are disclosed. More particularly, these compounds possess histamine H3 receptor antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3 receptor blockade is beneficial.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: July 9, 2002
    Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbH
    Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen